

Background

Cancer genomics studies have transformed the field of Oncology, from more accurate diagnostic tests to precision treatment. However, cancer genomics studies produce massive, heterogeneous datasets with variable technical characteristics, study parameters, and ontologies. Some of these characteristics include the preprocessing of data, file formats, attribute names, and or reference material. These inconsistencies between different studies and datasets create challenges for data integration, analysis, interpretation of results, and extrapolation of meaningful observations. Consequently, attempting to utilize, analyze, or combine datasets from multiple sources proves inefficient and overly complicated. OncoMX (https://www.oncomx.org/) is a knowledgebase and web portal actively being developed to quell such challenges by leveraging biomedical ontologies to unify disparate data while emphasizing the availability of multi-faceted evidence for cancer biomarkers. With advances in cancer genomics technologies, studies regarding cancer biomarkers have become an integral aspect of cancer research. A biomarker can be defined as a measurable (proteomic, genomic, metabolomic, epigenetic, etc.) substance in an organism that indicates the occurrence of disease, infection, or possibly environmental exposure. Genomic biomarkers, such as mutations in the BRCA1 and BRCA2 genes, are examples of highly penetrant biomarkers whose upregulation significantly increases the incidence of breast cancer. In response to the influx in cancer genomic data, OncoMX has created a space to explore multiple data sources in one database.

What is OncoMx?

OncoMX is a knowledgebase and web portal developed to address many of the aforementioned challenges by streamlining searches between unified datasets. OncoMX is a collaborative project between The George Washington University, NASA's Jet Propulsion Laboratory, the Swiss Institute of Bioinformatics, and the University of Delaware. The collective OncoMX mission is to create an integrated cancer mutation and expression resource for exploring cancer biomarkers to improve early cancer detection. OncoMX currently integrates sequencing-based mutation data from BioMuta, cancer/normal differential expression data from BioXpress, normal expression data across organisms from Bgee, biomarker data from EDRN, and literature mining through custom applications of DEXTER and DiMeX.

BioMuta and BioXpress serve as the foundational knowledgebases for OncoMX, where data is unified through Disease Ontology and Uberon Anitomical Entity terms. BioMuta is a database of single nucleotide variations (SNVs) associated with cancer, where variations are mapped to genomic coordinates and RefSeq nucleotide entries, and unified through UniProtKB/Swiss-Prot positional coordinates. BioXpress is a database of RNA-Seq and miRNA-seq expression data that has been analyzed for differential expression associated with cancer.

Normal expression data from Bgee is added to give context to the differential expression analysis. Bgee is a database of annotated gene expression evolution data from model organisms. Gene expression data in Bgee is annotated with Uberon Anatomical Entity terms, Developmental State terms, homology ontology, and confidence information ontology. EDRN is a database of cancer biomarker information which facilitates the synthesis of clinical applications from biomarker information, early cancer state testing, and cancer risk testing. Finally, the custom literature mining software DEXTER and DiMeX augment the cancer data to improve functional interpretation of the reported variants and expression profiles. DEXTER is an automated literature-mining tool

that extracts gene and miRNA expression information associated with disease from literature, whereas DiMeX extracts relationships about mutation in cancer.

Supplemental data integrated into the OncoMX database include functional annotations, scRNA-seq analysis, hepatocellular carcinoma serum glycoprotein N-glycan intensity measures, neoepitopes caused by mutations in cancer, and updated cancer mutation and expression literature mining results. OncoMX also houses custom datasets through the parallel data site at data.oncomx.org.

OncoMX was designed, with key user input, to better facilitate cancer biomarker research and discovery through four major use cases: 1) exploration of cancer biomarkers, 2) evaluation of mutation and expression in an evolutionary context, 3) side-by-side exploration of published literature for mutation and expression in cancer, 4) and exploration of a specific gene or biomarker within a pathway context (see Figure 1). OncoMX is expected to benefit basic cancer research, promote efficient consumption of information by end users, and ultimately improve biomarker and cancer detection capabilities. The unification of multiple cancer datasets allows users to explore or generate hypotheses within one database, execute targeted searches, and compare data sources. OncoMX is projected to support a broad range of cancer research initiatives for the enrichment of cancer biomarker detection. This work is licensed under a Creative Commons Attribution 4.0 International License.



Where to start

The OncoMX dashboard has everything accessible within a few clicks (see Figure 2). The main OncoMX donut graph in the center of the page is an interactive graph comprising all the data integrated into OncoMX. By moving the cursor over the different sections of the circle, the user is able to see the data contributed by each resource. For example, when holding the cursor over the large dark blue sections of the donut, 33,172,849 data points are shown to be contributed from Bgee. By then clicking on the dark blue Bgee portion, the view expands to show another donut graph, broken down into subcomponents of Bgee data. On the outer edges, there are four segments containing links to additional useful information. The "Perspectives" list (in progress) will provide links to dashboards optimized for the four main use case perspectives. "Data Source" provides links to access all the

original data integrated into OncoMX. "Statistics at a Glance" offers a statistical summary organized by data source, and "News" displays a news feed of pertinent announcements and will eventually link to social media feeds. Clicking on any of the options in the tables leads you to specific data tables lower on the homepage or links out to separate pages with the corresponding information.



How to search

For the purposes of this tutorial, we will use the following biological question to demonstrate OncoMX features: Is the BRCA1 gene only upregulated in breast cancer?

As described above, options for exploring various contributing datasets can be accessed from the landing page (see Figure 3). The search bar can be found below the buttons for exploring datasets.



The user can perform a global search by entering either a gene symbol or a UniProtKB accession in the search box. This will allow the user to access different visualizations associated with the searched gene of interest. Further down in this tutorial, a use case is provided detailing how to perform a search and view and interact with the results. The user can navigate back to the OncoMX main page from the search results (or from any page) by clicking the "Home" tab in the upper menu bar or by clicking on the OncoMX logo. **Explore datasets**

As described above, the landing page has a number of options available for quick exploration of integrated datasets. Currently available data types include: Differential Expression, Biomarkers, Pathways, Disease Mutation, Normal Expression, Expression Literature Mining, and Mutation Literature Mining. The information included in each of these datasets is explained below.

Differential Expression

This table is indexed by gene/protein/mRNA or miRNA accession/name. In addition to text searching, you can use the filters on the left hand side of the table to filter rows by TCGA cancer types or by significance of differential expression. To access the gene detail view for a specific entry, click the hyperlinked gene symbol in the first column. Cross-references to numerous other resources can also be found in the table, including NCBI gene search, BioXpress entry, disease ontology, TCGA study, and Uberon ontology.

Column headers and descriptions for this table are as follows:

- **Gene/miRNA:** Official gene symbol approved by the HGNC, which is a short abbreviated form of the gene name, hyperlinked to the OncoMX detail view for this entry; if miRNA, this column will report the accession in the miRBase database
- UniProtKB/SwissProt AC: Hyperlinked UniProtKB accession (accession assigned to the protein isoform chosen to be the canonical sequence in UniProtKB database) linking to relevant entry in BioXpress
- **P-value:** P-value associated with reported differential expression
- Adj. P-value: P-value associated with reported differential expression adjusted for multiple testing
- Cancer Type: Mapped Cancer Disease Ontology slim term and link to relevant disease ontology page
- Log2 F.C.: Log2 fold change of expression of the gene/miRNA in tumor as compared to adjacent normal
- **Patient Freq.**: Proportion of patients whose individual observed trend of expression matches the cancer-wise trend
- RefSeq AC: RefSeq accession associated with the transcript
- **Significant**: Reports whether the observed change in expression was determined to be significant (adjpval < 0.05)
- TCGA Cancer: TCGA cancer acronym linked to the corresponding TCGA study page in NIH-NCI GDC
 Data Portal
- Anatomical Entity ID: Uberon anatomical entity ID corresponding to the diseased tissue

Biomarkers

This table is indexed by gene symbol or panel name.

Column headers and descriptions for this table are as follows:

- **Gene Symbol/Panel:** Official gene symbol or panel name, hyperlinked to the OncoMX detail view for this entry
- **Type:** Type of biomarker (can be Epigenetic, Gene, Genomic, Protein, or Proteomic)

- Associated Dataset: Dataset(s) associated with the biomarker as reported in EDRN database
- Is Panel:Denotes if entry is a biomarker or a panel
- Phase: Please see EDRN documentation
- **QA State**: Denotes whether biomarker has been curated, accepted, or is under review
- Organ: Organ in which biomarker is applicable (current options include Colon, Lung, Breast, and Ovary)
- **HGNC Symbol**: Official gene symbol approved by the HGNC, which is a short abbreviated form of the gene name
- **Reference Resource**: Hyperlinked references reporting biomarker activity
- **UniProtKB/SwissProt AC**:Accession assigned to the protein isoform chosen to be the canonical sequence in UniProtKB database (not applicable to panels)

<u>Pathways</u>

This table is indexed by UniProtKB/SwissProt AC and reports events associated with a given protein, its evidence, and the pathway to which the event belongs.

Column headers and descriptions for this table are as follows:

- **UniProtKB/SwissProt AC**: Accession assigned to the protein isoform chosen to be the canonical sequence in UniProtKB database hyperlinked to UniProtKB
- **Gene Symbol:** Official gene symbol approved by the HGNC, which is a short abbreviated form of the gene name, hyperlinked to the OncoMX detail view for this entry
- **Event**: Name of pathway event
- Evidence Code: Evidence code for gene/protein participation in the event (can be IEA or TAS)
- **Reactome Pathway ID**: Hyperlinked Reactome IDs for the corresponding pathway

Disease mutations

This table reports variants in cancer samples for each relevant in genomic and proteomic coordinates.

Column headers and descriptions for this table are as follows:

- **Gene Symbol** : Official gene symbol approved by the HGNC, which is a short abbreviated form of the gene name, hyperlinked to the OncoMX detail view for this entry
- UniProtKB/SwissProt AC: Hyperlinked UniProtKB accession (accession assigned to the protein isoform chosen to be the canonical sequence in UniProtKB database) linking to relevant entry in BioMuta
- RefSeq AC: RefSeq accession associated with the canonical transcript
- Cancer Type: Type of cancer associated with reported variant
- **Functional Impact:** Denotes whether a reported variant is associated with a functional loss or gain of acetylation, phosphorylation, glycosylation, or other functional annotation from UniProtKB, or prediction from PolyPhen or NetNGlyc2.0
- Genome Position: Genomic position of the variant
- Nuc. Position: Position of variant in nucleic acid sequence
- **Ref. Nuc:** Reference or wild-type nucleotide base
- Var. Nucleotide base resulting from variation
- **AA Position:** Position of variation in protein sequence
- **Ref. AA**: Reference or wild-type amino acid residue
- Var. AA: Amino acid residue resulting from variation

- **Polyphen2:** If applicable, lists the predicted effect of the variant reported by PolyPhen-2 (benign, possibly damaging, or probably damaging)
- **PMID:** If available, PMID(s) of manually curated or semi-automatically mined (using DiMeX) publication(s) associated with the reported variation
- **Source:** Data source of reported variation (can be CIViC, ClinVar, COSMIC, ICGC, or TCGA)
- Status: Status of study from which variation was obtained (LG for large-scale, SM for small-scale)
- Anatomical Entity ID: Uberon anatomical entity ID corresponding to the diseased tissue

Normal expression

This table reports the status of RNA-seq derived expression in normal samples.

Column headers and descriptions for this table are as follows:

- **Gene Symbol**:Official gene symbol approved by the HGNC, which is a short abbreviated form of the gene name, hyperlinked to the OncoMX detail view for this entry
- **UniProtKB/SwissProt AC:** Accession assigned to the protein isoform chosen to be the canonical sequence in UniProtKB database
- Ensembl Gene ID: Hyperlinked Ensembl gene ID linking to relevant entry in Bgee
- Anatomical Entity Name: Uberon anatomical entity name corresponding to sample tissue
- Developmental Stage Name: Uberon developmental stage name corresponding to sample tissue
- Expression Call: Indicates presence or absence of expression
- **Expression Rank:** The lower the rank, the higher the expression level
- **Call Quality:** Quality associated with call (can be high quality or poor quality)

<u>EDRN</u>

This tab summarizes biomarker details from EDRN.

Colum header and descriptions are as follows:

- **EDRN Title:** Name given to biomarker in EDRN
- Organ: Organ in which biomarker is applicable (current options include Colon, Lung, Breast, and Ovary)
- **Phase:** If available, reports the designation of the biomarker as one of five phases (Phase 1, Preclinical Exploratory; Phase 2, Clinical Assay and Validation; Phase 3, Retrospective Longitudinal; Phase 4, Prospective Screening; Phase 5, Cancer Control)
- **QA:** Denotes whether biomarker has been curated, accepted, or is under review
- Aliases: Other names/descriptions of the biomarker
- **Description:** States the purpose and scope of the biomarker

Mutation literature mining

This table displays hits for literature-mined mentions of mutation in cancer using a customized application of DiMeX.

Column headers and descriptions for this table are as follows:

- **PMID**: PMID(s) of mined (using DiMeX) publication(s) containing variant information
- UniProtKB/SwissProt AC: Accession assigned to the protein isoform chosen to be the canonical

sequence in UniProtKB database

- **Gene Symbol**: Official gene symbol approved by the HGNC, which is a short abbreviated form of the gene name
- Entrez ID: Unique, stable, and tracked integer identifier
- Gene Mention: Specific form/spelling of gene mentioned in the retrieved publication
- DOID: Mapped Cancer Disease Ontology slim ID
- DOID Name: Mapped Cancer Disease Ontology slim term
- **Disease Mention**: Specific form/spelling of disease mentioned in the retrieved publication
- Mutation Mention: Specific form of substitution mutation mentioned in the retrieved publication
- **Mutation Type:** Specifies whether the mutation is mentioned in terms of amino acid or nucleotide substitutions and coordinates
- Abstract Extraction: Section of abstract from which the relevant sentence was extracted
- Sentence Number: Number of sentence extracted
- Sentence Text: Text of sentence extracted
- Extraction Method: Denotes whether relationship in sentence was an association or other
- Patient/Control Numbers: If available, reports the number of patients and/or controls in the study
- Is Meta-Analysis: Denotes if the publication was a meta-analysis
- Is Review: Denotes if the publication was a review

Expression literature mining

This table displays hits for literature-mined mentions of expression in cancer for both genes and miRNAs using a customized application of DEXTER.

Column headers and descriptions for this table are as follows:

- **UniProtKB/SwissProt AC:** Accession assigned to the protein isoform chosen to be the canonical sequence in UniProtKB database
- Entrez ID: Unique, stable, and tracked integer identifier
- Gene Mention: Specific form/spelling of gene mentioned in the retrieved publication
- miRNA Number: Number/ID of miRNA mentioned in publication
- miRNA Mention: Specific form/spelling of miRNA mentioned in the retrieved publication
- **PMID:** PMID(s) of mined (using DEXTER) publication(s) containing expression information
- DOID: Mapped Cancer Disease Ontology slim ID
- DOID Name: Mapped Cancer Disease Ontology slim term
- **Disease Mention:** Specific form/spelling of disease mentioned in the retrieved publication
- **Disease Extracted From:** Section of the publication from which the disease mention was extracted
- Expression Level: Reports whether the expression change was reported to go up or down in disease
- Sentence Type: Type of sentence, strength of assertion is strongest is Type A
- Sample 1: Denotes the first (or only) group compared in the extracted sentence
- **Sample 2:** If the extracted sentence contains a comparison between two groups, denotes the second group compared in the extracted sentence
- Is Same Patient: Reports whether a comparison is performed between two groups of samples from a single patient
- Sentence Text: Text of sentence extracted

Explore statistics and data sources

In addition to providing access to datasets, the landing page also has options for accessing gene statistics and

downloading contributing datasets in their original forms.

Statistics at a Glance

As described above, clicking on any of the topics listed here or interacting with the Circos plot will toggle the charts displayed below. Statistics can be viewed as a series of charts across multiple resources (Total Cancer Terms and Proteins) or for each primary contributing resource (Biomarkers from EDRN, BioMuta, and BioXpress). Additional summary views will be added in subsequent releases.

Data Sources

The core underlying knowledgebase of OncoMX is derived from BioMuta and BioXpress integrated cancer mutation and expression databases. Normal expression data from Bgee and custom text mining software, DiMeX and DEXTER, augment the cancer data to improve functional interpretation of the reported variants and expression profiles. Where relevant, data are mapped to Disease Ontology and Uberon Anatomical Entity ontology terms to facilitate better integration. All data are wrapped into the OncoMX database and web portal, mapped to additional functional information from NCI Early Detection Research Network (EDRN) and Reactome. In version 1.0, cancer mutation and expression data are taken from: CIViC, ClinVar, COSMIC, ICGC, IntOGen, and TCGA.

While this section allows previewing of data sources, scrolling further down on the main page to the "External Downloads" section will provide access to full data dumps. Clicking any of the contributing source buttons will initiate a download.

For more information regarding pipelines of contributing resources, please refer to the following:

- Bgee: <u>https://bgee.org/</u>
- BioMuta: <u>https://hive.biochemistry.gwu.edu/biomuta</u>
- BioXpress: <u>https://hive.biochemistry.gwu.edu/bioxpress</u>
- DEXTER: https://academic.oup.com/database/article/doi/10.1093/database/bay045/5025486
- DiMeX: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0152725
- EDRN: https://edrn.nci.nih.gov/
- Reactome: <u>https://reactome.org/</u>

OncoMX use case

A major strength of the OncoMX portal is that the user can visualize all the data in one place for a specific gene by clicking on different tabs. The use case below illustrates how we can visualize all the different cancers expressed in a single gene including corresponding normal tissue expression and biomarkers in OncoMX. In this use case, we will use the example of BRCA1 to demonstrate search and overall website functionality.

To search for the gene, go to the OncoMX homepage at <u>www.oncomx.org</u> and type your gene of interest in the search box. PLEASE NOTE: Throughout the use case, special formatting is used to distinguish between various types of text the user may see or input in the website. Labels within the portal are denoted by <u>underlined, bolded text</u>, commands the user should perform are denoted in plain **bold text**, and data sources are denoted by <u>italicized, underlined, bold text</u>.

0	ncø	M	X	
BRCA1 BIOMARKER	S DIFFERENTIAL EXPR	d related data	Q PATHWAYS	
	HEALTHY EXPRESSION	EXPRESS BROWSE D	ION LITERATURE MINING	
	More			
	Figure 4. General	gene sea	arch	

This will bring the user to a page that provides an overview of the search results for the gene of interest and other associated data of the gene of interest as illustrated below:

arch Results							
EDRN Biomarkers:	3	FDA Biomarkers:	3	Disease Mutations:	907	Differential Expression:	12
Healthy Expression:	617	Mutation Literature Mining:	809	Expression Literature Mining:	33	Reactome:	45



Step 2:

The first tab is a graphical representation of <u>Cancer bulk RNA-seq</u> which shows the frequency of expression trends for each cancer type. The green bar denotes up-regulation where the red shows down-regulation of the gene as illustrated below.



Users can **hover** over any plot point to get quantitative information about the plot along. For example, when you hover over the first bar you should see popups describing <u>Thyroid cancer</u>, <u>47.6%</u> of samples are <u>Down</u> <u>Regulated</u> and <u>52.4%</u> are <u>Up Regulated</u>.

<u>Step 3:</u>

Click on **<u>Human healthy bulk RNA-seq</u> to view the graphical plot of normal tissue expression and the levels at which the searched gene is being expressed. The silver** bars denote absent expression levels, **red** denotes low expression, **green** denotes medium expression, and **blue** high expression.



<u>Step 4:</u>

The user may also compare normal expression levels in different tissues in mouse data using the same criteria of scoring as the human data as illustrated below by **clicking** on the **Mouse normal RNA-seq** tab.



<u>Step 5:</u>

Click on the **<u>Mutation</u>** tab to see the graphical representation of mutation frequencies for various cancer types for the BRCA1 gene.



<u>Step 6:</u>

Click on the **Expression Literature Mining** tab to visualize the number of publications with evidence supporting the searched gene having some relationship between gene expression and each cancer type.



Step 7:

Click on the <u>Mutation Literature Mining</u> tab to visualize the number of publications reporting the searched gene to be mutated for each cancer type. Note, that there is currently no literature mutation data for this gene. The pilot dataset for mutation literature mining was exclusively for lung cancer. A new version of mutation literature mining results is actively being added to the database and should be available with the next update.



<u>Step 8:</u> To further explore data sources associated with this gene, **scroll down** to the <u>Details on this gene and all</u> <u>associated data sources</u>. The first tab is <u>Biomarkers</u> where the users can view biomarker information on the BRCA1 gene retrieved from the Early Detection Research Network (EDRN) and the FDA Approved biomarkers for breast cancer public biomarker record.

Nort Details VTILE SEC11 Organ: Breast Phase: Two QA: Curated Eff Interview II and/ press/, breast and ourdan cancer susceeptibility protein 1_ RRG Reproved biomations on cancer susceeptibility protein 1_RRGP_EC 6.3.2.*, RNF53	rkers	BioMuta BioXp	ress Bgee	DEXTER	DiMeX						
etc Link Link Link Link Link Krister 1, asky onset, breast and ovarian cancer subuceptibility protein 1, FRIGF inger motion 53_PNCAA_protein (PASP-Baland 1, equilatory suburit 55_breast type 15_subceptibility protein 1_PSCP_EC 6.3.2.v_RNF33_ U_RRS_BROCT_PPP1RB3_BROVCA1 V_RS_BROCT_PPP1RB3_BROVCA1 BRCA1/BRCA2-containing complex_suburit 1_breast and ovarian cancer subusceptibility protein 1_PSCP_EC 6.3.2.v_RNF33_ U_RRS_BROCT_PPP1RB3_BROVCA1 V_RS_BROCT_PPP1RB3_BROVCA1 BRCA1/BRCA2-containing complex_suburit 53_breast targe multi-suburity trades complexes as a turnor suppressore. BRCA1 combines with other turnor suppressors_DNA damage sensors_and signal transducers I targe multi-suburity trades complexes. This protein thus pays a role in transcription_DNA repair of double-stranded breaks_and thermitation. Mutations in this gene are responsible for approximately 40% of interified breakst cancers and more than 80% of interified breakst, and thermitation. Over Image multi-suburity trades in formation Breakst information Over Image multi-suburity 40% of interified breakst cancers and more than 80% of interified breakst, and thermitation. Optionarities Image multi-suburity 40% of interified breakst cancers and more than 80% of interified breakst, and thermitation. Optionarities Image multi-suburity 40% of interified breakst cancers and more than 80% of interified breakst. Optionarities Image multi-suburity 40% of interified breakst cancers and more than 80% of interified breakst. Optionarities Image multi-suburity 40% of interified breakst cancers and more than 80% of interified	arker Det	ails RCA1		Oroan: Bre	ast		Phase: Two		QA: Cu	rated	
r hyse 1 susceptibility protein 1_PBCP_EC 5.3.2RNF53_ VIRS_BRCC/_PPF1RS_BRCVCA1 VIRS_BRCC/_PPF1RS_BRCVCA1 VIRS_BRCC/_PPF1RS_BRCVCA1 VIRS_BRCC/_PPF1RS_BRCVCA1 VIRS_BRCC/_PPF1RS_BRCVCA1 VIRS_BRCC/_SOUTHOUTS VIRS_BRCC/	ist cancer	1_early onset_brea	st and ovarian can	cer susceptibility	protein 1	_ RING fing	per protein 53_PNCA4_pr	otein phosphat	ase 1_ regu	latory subunit	53_breast
Interaction 22andMe PGS Gendic Health Risk Report of Sander 22andMe PGS Gendic Health Risk Report of Sander 22andMe PGS Gendic Health Risk Report of Sander 22andMe PGS SandMe PGS Gendic Health Risk Report for SandMe PGS Gendic Health Risk Report of Sander 22andMe PGS SandMe PGS SandMe PGS Gendic Health Risk Report of Sander 22andMe PGS SandMe PGS	cer type 1 CAI_IRIS_	BRCC1_PPP1R53	BRCA1/BRCA2- BROVCA1	containing comp	ex_subu	nit 1_breas	t and ovarian cancer susus	ceptibility prot	ein 1_PSCF	P_EC 6.3.2	RNF53_
a large multi-subult protein complex known as the BRCA1-associated genome surveillance complex (BASC). BRCA1 associates with NAA polymorase II, and machination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than BD% of inherited breast and ovarian cancers. Adaptived biomarker information Tor	CA1 is a nu	clear phosphoprotei	in that functions as	a tumor suppres	sor. BRC	A1 combine	s with other tumor suppres	sors_ DNA da	mage senso	rs_ and signal	transducers to
biblinations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Hullestions: 5522 Approved biomarker information Trade Name Manufacturer Bubmiscion Pane Symbol AC Biomarker Biomarker NCIT See Trade Name Manufacturer Bubmiscion Pane Symbol AC BIOmarker Created Origin Biomarker See Trade Name Denviron Bubmiscion Pane Bymbol AC Biomarker Biomarker Origin Biomarker See Created Origin Biomarker 23andMe PGS Gene Denviron Pane Breast 23andMe PGS Gene Denviron Pane Breast Breast Cancer BRCA1BRCA2 (Selected Variants) Denviron Pane Breast Cancer BRCA1BRCA2 (Selected Variants) Denviron Pane Breast Denviron Pane Breast Denviron Pane Breast Denviron Pane Breast Breast Cancer BRCA1BRCA2 (Selected Variants)	n a large m C-terminal	ulti-subunit protein o domain_ also intera	omplex known as t cts with histone de	the BRCA1-asso acetylase compl	ciated ge exes. This	nome surve s protein thu	illance complex (BASC). B Is plays a role in transcripti	RCA1 associat on_ DNA repai	tes with RN/ r of double-s	A polymerase I stranded break	I_and through s_and
5522 A approved biomarker information Tore 10 entries search: 520 20 20 20 20 20 20 20 20 20 20 20 20 2	mbination. RN Publice	Mutations in this ge tions:	ine are responsible	for approximate	ly 40% of	f inherited b	reast cancers and more the	in 80% of inhe	rited breast	and ovarian ca	incers.
Diseased Trade Name Manufacturer Submission Lie Gene UniProtKBI Bwiss Prod Biomarket Diseased Diseased Trade Name Manufacturer Bubmission Is Gene UniProtKBI Bwiss Prod Eliomarket Diseased Diseased Created Diomarket NCIT Jsee Trade Name Manufacturer Bubmission Panel Senes UniProtKBI Bwiss Prod Eliomarket DCIT Biomarket NCIT Biomarker Trade Name Manufacturer Bubmission Panel Senes UniProtKBI Bwiss Prod Eliomarket NCIT Biomarker Sandhe BECA1 Panel Senes UniProtKBI Bwiss Prod BIomarket NCIT Breast Cancer 1 Eliomarket Senest <	86622										
Averapproved Excitation Hormation Now 10 rested Excitation Disease Trade Name Manufacturer Bubmiccion Panel Symbol AC Disease Trade Name Manufacturer Bubmiccion Panel Symbol AC Disease Canadic Health Risk Raport for BRCA11BRCA2 Braat Braat Canadic Health Risk Raport for BRCA11BRCA2 BRCA11BRCA2 Canadic Health Risk Raport for BRCA11BRCA2 Canadic Health Risk Raport for BRCA1 Canadic Health Risk Raport for Canadic Health Risk Rapo											
Dicescet Trade Name Manufacturer Bubmicsion Ic Gene UniProfrike/BisviceProt Biomarker ID Created Origin Biomarker Jsee Trade Name Manufacturer Bubmicsion Ic Gene Symbol AC Created Origin Biomarker Dicescet Genetic Health Risk Raport for Benatic Risk Raport for Cancer 1 Benatic Risk Raport for Variantes) 23andMe DEN170046 Y BRCA1 P38398 B99 I I I I I I I I I I I I I I I I I I	-DA appro	oved biomarker in	formation								
Disease Trade NameManufacturerManufacturerBubmitscionGene SymbolUniProtKB/BwisseProt ACBiomarket IDCreaseBiomarket OriginNCIT Biomarket23andMa PGS Genetic Health ZancerZ3andMa PGS Genetic Health ZancerZ3andMa PGS Genetic Health Cancer 1 BRCA1/BRCA2Z3andMeDEN170046YBRCA1 BRCA1P38398899ISomatic Final ActionBreast Genetic BRCA1/BRCA2	how 10	✓ entries						8	earch:		
JseeTrade NameManufacoturer8 ubmissionPanel8 ymbolACIDCreatedOriginBiomarkerJsee	Disease				16 (Gene ()	UniProtKB/8wissProt	Blomarker		Blomarker	NCIT
Breast Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) 23andMe DEN170046 Y BRCA1 P38398 899 somatic Gene_ BRCA1 Selected Variants) 23andMe DEN170046 Y BRCA1 P38398 899 somatic Gene_ BRCA1 Gene_ BRCA1 Gene_ BRCA1 Gene_ BRCA1 Gene_ BRCA1	Use	Trade Name	Manufacturer	8ubmission	Panel	8ymbol	AC	ID	Created	Origin	Blomarke
Breast Genetic Hoalth Eachor I BRCA11BRCA2 (Selected Variants)											
Breast Breast Cancer 1 Breast Cancer 1 Breast Breast Breast Breast Breast Breast Breast Breast Breast Breast Breast Breast Breast Breast Breas											
Breast Breast Breast Breast Breast Cancer 1_ Early Onset Gene (Selected Variants) Breast Cancer 1_ Early Onset Gene (Selected Variants) Breast Cancer 1_ Early Onset Gene BRCA1 Breast Cancer 1_ Early Onset Gene BRCA1											
Breast Breast Cancer 1 Breast Cancer 1 Breast Breast Breast Breast Breast Breast Breast Breast Breast Breast Cancer 1 Breast Breast Cancer 1 Breast Breast Cancer 1 Breast Breast Cancer 1 Breast											
Breast Risk Report for Cancer 1 Early Onset Cancer											Durant
Breast Brack Beach Genetic Health Cancer BRCA1/BRCA2 (Selected Variants) 23andMe DEN170046 Y BRCA1 P38398 899 somatic (Selected Variants) BRCA1/BRCA2 (Selected Variants) BRCA1											Cancer 1_
Ganelic Health Breast Risk Report for Cancer BRCA1/BRCA2 (Selected Variants) DEN170045 Y BRCA1 P38398 899 somatic mutation Variants Gane_ BRCA1 BRCA1 BRCA1 Selected Variants BRCA1		23andMo PGS									Onset
Cancer BRCA1/BRCA2 (Selected Variants) DEN170046 Y BRCA1 P38398 899 mutation Repair (Selected Variants) BRCA1 B	Desart	Genetic Health									Gene_ BRCA1
(Selected Associate: Variants) Gane_ BRCA1 BRCA1	Cancer	BRCA1/BRCA2	23andMe	DEN170046	Y	BRCA1	P38398	899		mutation	DNA Repair
BRCA1 Gene_ BRCA1		(Selected Variants)									Associated
BRCA1											BRCA1
											BRCA1

<u>Step 9:</u> Click on <u>BioMuta</u> to view the mutation source data.

		_		Jeta	lis on tr	ns g	ene	and all t	ne asso	clated da	ata sour	ces		
EDRN	BioMuta	BioXpres	is I	Bgee	Reactome	e F	DA Bio	omarker						
Mutation	Details													
Show 10	• entries	Nuo	Dof	Vor		Dof	Vor			Cancor		Searc	h:	Anatomical Entity
AC	Position	Position	Nuc.	Nuc.	Position	AA	AA	Polyphen2	PMID [†]	Type +	Source [†]	Impact	Status	ID
		-	•		101	Y	x		18679828	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
-		-		-	71	R	G	possibly damaging	19123044	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
-	-	-	-	-	1699	R	Q	probably damaging	19563646	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
-	-	-		-	18	м	т	possibly damaging	19563646	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
	-	-	-	-	1655	s	F	probably damaging	19563646	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
	-	-			67	D	E	possibly damaging	19865540	DOID:1612 / Breast cancer [BRCA]	Literature mining		SM	UBERON_0000310
	-	-			1051	т	s	benign	19865540	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
	-	-		-	44	с	s	probably damaging	20437199	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
-	-	-	-	-	61	с	G	benign	20514903	DOID:1612 / Breast cancer [BRCA]	Literature mining	-	SM	UBERON_0000310
-	-	-	-	-	1008	м	ı.	benign	18798010	DOID:2394 / Ovarian cancer [OVCA]	Literature mining	-	SM	UBERON_0003134
Showing	1 to 10 of 4,9	37 entries								Previou	s 1 :	2 3 4	5	494 Next

<u>Step 10:</u> **Click** on <u>*BioXpress***</u>** to visualize the differential expression data for the queried gene.</u>

			Detai	ls on this	gene	and all the	associate	d data so	ource	S
EDRM	I BioMuta	BioXpre	ss Bgee	Reactome	FDA B	omarker				
Expre	ession Details	5								
Show	10 v entrie	95								Search:
Log F.C.	P-value	Adj. P- value	♦ Significant	Expression Trend	TCGA Study	Cancer Type	Patient Freq.	Source $^{\diamond}$	PMID	Anatomical Entity ID
-0.1	0.61	1	No	Down	COAD	DOID:219 / Colon cancer [Colca] & DOID:234 / Colon adenocarcinoma	2/26(7.69)	RNASeqV2	-	UBERON:0001155
0.19	0.325	0.52	No	Up	LIHC	DOID:3571 / Liver cancer [Livca]	35/50(70.0)	RNASeqV2	-	UBERON:0002107
-0.44	5 0.313	1	No	Down	READ	DOID:1993 / Rectum cancer [Recca] & DOID:1996 / Rectum adenocarcinoma	1/6(16.67)	RNASeqV2	-	UBERON:0001052
-0.4	0.259	0.808	No	Down	PAAD	DOID:1793 / Pancreatic cancer [PACA] & DOID:4074 / Pancreas adenocarcinoma	1/4(25.0)	RNASeqV2	-	UBERON:0001150&UBERON:0001264
0.26	0.213	0.391	No	Up	STAD	DOID:10534 / Stomach cancer [Stoca]	29/32(90.63)	RNASeqV2	-	UBERON:0000945
-0.18	3 0.165	0.247	No	Down	THCA	DOID:1781 / Thyroid cancer [Thyca]	28/59(47.46)	RNASeqV2		UBERON:0002046
0.26	0.123	0.666	No	Up	LUAD	DOID:1324 / Lung cancer [Lunca] & DOID:3910 / Lung adenocarcinoma	48/58(82.76)	RNASeqV2	-	UBERON:0002048
0.18	0.0734	0.119	No	Up	PRAD	DOID:10283 / Prostate cancer [PCa]	34/52(65.38)	RNASeqV2	-	UBERON:0002367
0.55	0.0108	0.335	No	Up	KICH	DOID:263 / Kidney cancer [Kidca] & DOID:4471 / Chromophobe adenocarcinoma	6/25(24.0)	RNASeqV2	-	UBERON:0002113
1.25	0.00131	0.00615	Yes	Up	UCEC	DOID:363 / Uterine cancer [Uteca]	6/7(85.71)	RNASeqV2	-	UBERON:0003134
Show	ing 1 to 10 of 1	8 entries				. ,				Previous 1 2 Next

<u>Step 11:</u> **Click** on <u>**Bgee**</u> to see normal expression data for human and mouse in a tabular format.

EDRN BioMuta	BioXpress Bgee	Reactome FD	A Biomarker				
Bgee Details							
Show 10 • entries	5				Search:		
Anatomical Entity ID	Anatomical Entity Name	Developmental Stage ID	Developmental Stage Name	Expression Lvl	Expression LvI - Anatomical	Call Quality	Expression Rank
UBERON:0000473	testis	HsapDv:0000092	human middle aged stage (human)	HIGH	HIGH	GOLD	5.18e3
UBERON:0002107	liver	HsapDv:0000090	25-44 year-old human stage (human)	HIGH	HIGH	GOLD	9.07e3
UBERON:0002107	liver	HsapDv:0000092	human middle aged stage (human)	HIGH	HIGH	GOLD	9.26e3
UBERON:0000992	female gonad	HsapDv:0000092	human middle aged stage (human)	HIGH	HIGH	GOLD	1.05e4
UBERON:0000473	testis	HsapDv:0000090	25-44 year-old human stage (human)	HIGH	HIGH	GOLD	1.06e4
UBERON:0000948	heart	HsapDv:0000092	human middle aged stage (human)	MEDIUM	HIGH	GOLD	1.16e4
UBERON:0002046	thyroid gland	HsapDv:0000091	human late adulthood stage (human)	MEDIUM	HIGH	GOLD	1.20e4
UBERON:0002084	heart left ventricle	HsapDv:0000092	human middle aged stage (human)	MEDIUM	HIGH	GOLD	1.27e4
UBERON:0002084	heart left ventricle	HsapDv:0000087	human adult stage (human)	MEDIUM	HIGH	GOLD	1.27e4
UBERON:0000948	heart	HsapDv:0000094	65-79 year-old human stage (human)	MEDIUM	HIGH	GOLD	1.28e4
Showing 1 to 10 of 30	12 entries			Previous	1 2 3 4	5	31 Next

<u>Step 12:</u> **Click** on <u>**Reactome**</u> to for a list and links to the pathways associated with this specific gene search provided by Reactome.

DRN BioMuta	BioXpress	Bgee Reactome FDA Biomarke	r		
Reactome Details					
how 10 🔻 entries			Search:		
UniProtKB/SwissProt AC	Pathway ID	URL ÷	Event	Evidence Code	Species
P38398	R-HSA- 2997616	http://reactome.org/PathwayBrowser/#/R- HSA-2997616	PIAS1,4 SUMOylates BRCA1 with SUMO2,3	TAS	Homo sapiens
P38398	R-HSA- 2997709	http://reactome.org/PathwayBrowser/#/R- HSA-2997709	PIAS1,4 SUMOylates BRCA1 with SUMO1	TAS	Homo sapiens
P38398	R-HSA- 5659781	http://reactome.org/PathwayBrowser/#/R- HSA-5659781	BRCA1 forms a heterodimer with BARD1	TAS	Homo sapiens
P38398	R-HSA- 5683385	http://reactome.org/PathwayBrowser/#/R- HSA-5683385	Formation of BRCA1-A complex at DNA DSBs	TAS	Homo sapiens
P38398	R-HSA- 5683735	http://reactome.org/PathwayBrowser/#/R- HSA-5683735	CHEK2 is recruited to DNA DSBs	TAS	Homo sapiens
P38398	R-HSA- 5683801	http://reactome.org/PathwayBrowser/#/R- HSA-5683801	CHEK2 phosphorylates BRCA1	TAS	Homo sapiens
P38398	R-HSA- 5684052	http://reactome.org/PathwayBrowser/#/R- HSA-5684052	PIAS4 SUMOylates MDC1	TAS	Homo sapiens
P38398	R-HSA- 5684071	http://reactome.org/PathwayBrowser/#/R- HSA-5684071	RNF4 ubiquitinates MDC1	TAS	Homo sapiens
P38398	R-HSA- 5684108	http://reactome.org/PathwayBrowser/#/R- HSA-5684108	BRCA1 binds phosphorylated RBBP8	TAS	Homo sapiens
P38398	R-HSA- 5684875	http://reactome.org/PathwayBrowser/#/R- HSA-5684875	Binding of ATR: ATRIP to RPA at resected DNA DSBs	TAS	Homo sapiens

Step 13:

Click on the *FDA Biomarker* tab to see the custom generated dataset of FDA approved breast cancer biomarkers.



Contact and Availability

For more information, scroll all the way down from the main page to submit a contact request via webform.

For access to newest features, you can visit our beta site - https://beta.oncomx.org/

OncoMX is licensed under a Creative Commons CC By 4.0 Attribution International license.